Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 5,916,763 | 5,465,693 | 6,344,359 | 7,013,446 | 6,148,851 | 30,889,112 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 5,916,763 | 5,465,693 | 6,344,359 | 7,013,446 | 6,148,851 | 30,889,112 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 5,557,884 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 25,331,228 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 5,916,763 | 5,465,693 | 6,344,359 | 7,013,446 | 6,148,851 | 30,889,112 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,178 | 1,357 | 1,402 | 28,829 | 212,398 | 247,164 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 31,162,199 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: | RESEARCH: DESPITE BEING THE LEADING CAUSE OF CANCER MORTALITY, LUNG CANCER RECEIVES FAR LESS RESEARCH FUNDING PER DEATH. LUNG CANCER RECEIVES $3,580 PER DEATH COMPARED TO BREAST CANCER AT $19,050, PROSTATE CANCER AT $8,116, AND PANCREATIC CANCER AT $4,796. THAT IS WHY FUNDING FROM NON-GOVERNMENTAL ORGANIZATIONS IS SO CRITICAL. THE LUNG CANCER RESEARCH FOUNDATION (LCRF) PLAYS A PIVOTAL ROLE IN THIS FUNDING LANDSCAPE. SINCE 2005, THE LUNG CANCER RESEARCH FOUNDATION, AND ITS PROGENITOR ORGANIZATIONS, HAS BEEN COMMITTED TO FUNDING CUTTING EDGE RESEARCH THAT TRANSFORMS THE LUNG CANCER TREATMENT LANDSCAPE. WHEN WE FIRST OPENED OUR DOORS, OUR MISSION WAS SIMPLE: PROVIDE HOPE BY FUNDING THE BEST RESEARCH AND HELP BRING IT TO PEOPLE. WE HAVE BEEN WILDLY SUCCESSFUL. IN 18 YEARS, WE HAVE BECOME ONE OF THE LARGEST PRIVATE FUNDERS OF LUNG CANCER RESEARCH ENABLING EARLIER DETECTION, DEEPER UNDERSTANDING OF THE MECHANISMS THAT ALLOW LUNG CANCER TO FORM, AND NEW AND EXPANDED TREATMENT OPTIONS THAT HAVE SAVED MANY LIVES. SIMULTANEOUSLY, OUR SCIENTIFIC ADVISORY BOARD HAS BECOME ONE OF THE PREEMINENT BODIES IN THE LUNG CANCER RESEARCH COMMUNITY. FURTHERMORE, OUR INVESTMENT IN EARLY CAREER INVESTIGATORS CONTINUES TO ALLOW NEW TALENT TO THRIVE AND GROW IN THE SPACE AS IS DEMONSTRATED THROUGH FOLLOW-ON FUNDING MANY HAVE RECEIVED SINCE RECEIVING THEIR LCRF GRANT. TO DATE, LCRF HAS PROVIDED 419 RESEARCH GRANTS TOTALING NEARLY $44 MILLION, THE LARGEST AMOUNT PROVIDED BY A NON-GOVERNMENTAL ORGANIZATION DEDICATED TO FUNDING LUNG CANCER RESEARCH. SUPPORT WITHIN THE PATIENT COMMUNITY, RESEARCHERS, STRATEGIC PARTNERS, AND INDUSTRY PARTNERS IS KEY TO OUR PRESENT SUCCESS AS WELL AS ACHIEVING OUR FUTURE VISION TO FIND A CURE FOR LUNG CANCER. DURING 2023, WE FUNDED TEN (10) RESEARCH GRANTS ACROSS FIVE (5) RESEARCH GRANT TRACKS. TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF LEADING EDGE RESEARCH GRANT PROGRAM WHICH FUNDS INNOVATIVE PROJECTS ACROSS THE FULL SPECTRUM OF BASIC, TRANSLATIONAL, CLINICAL, EPIDEMIOLOGICAL, HEALTH SERVICES, AND RESEARCH FOCUSED ON A MYRIAD OF TOPICS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - INVESTIGATING NOVEL SYNTHETIC LETHAL VULNERABILITIES IN EGFR-DRIVEN LUNG CANCER - DEEP WHOLE GENOME SEQUENCING OF CIRCULATING TUMOR DNA FOR STUDYING EVOLUTION AND THERAPY RESISTANCE IN SMALL CELL LUNG CANCER TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF RESEARCH GRANT ON UNDERSTANDING RESISTANCE IN LUNG CANCER. THESE PROJECTS WILL FOCUS ON UNDERSTANDING THE DEVELOPMENT, PREVENTION, AND THERAPY OF RESISTANCE BY SUPPORTING PROJECTS THAT ARE IDENTIFYING, CHARACTERIZING, TREATING OR PREVENTING RESISTANCE TO THERAPIES IN LUNG TUMOR CELLS, TISSUES, MOUSE MODELS, AND/OR PATIENTS. THESE STUDIES WILL ENHANCE THE MOMENTUM OF IMPROVING LUNG CANCER OUTCOMES AND HAVE THE POTENTIAL TO INCREASE SURVIVORSHIP. THESE PROJECTS WILL EXPLORE THE FOLLOWING: - CHARACTERIZATION AND THERAPEUTIC TARGETING OF A TUMOR-TUMOR MICROENVIRONMENT NETWORK PROMOTING RESISTANCE TO TARGETED THERAPY IN LUNG CANCER - UNCOVERING NOVEL VULNERABILITIES TO TREAT SCLC THERAPY RESISTANCE TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA). MINORITY APPLICANTS ARE LESS LIKELY TO RECEIVE GRANTS, TO HAVE THE R PHASES OF K01 OR K99 AWARDS ACTIVATED, NEED MORE SUBMISSIONS TO OBTAIN FUNDING, AND OFTEN WILL NOT RESUBMIT PROPOSALS. AS MINORITY APPLICANTS MUST OVERCOME SYSTEMIC AND STRUCTURAL BARRIERS DUE TO RACE, ETHNICITY, COUNTRY OF ORIGIN, SOCIOECONOMIC STATUS, AND/OR LANGUAGE, MANY LEAVE ACADEMIA WHICH FURTHER EXACERBATES THE LACK OF DIVERSITY IN SCIENCE, TECHNOLOGY, ENGINEERING AND MATHEMATICS (STEM) AND MEDICAL FIELDS. TO PROVIDE PROTECTED TIME AND MENTORING TO THESE TRAINEES, WE CONTINUE TO OFFER THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA) FOR LUNG CANCER FOR MINORITY POSTDOCTORAL/CLINICAL FELLOWS AND ASSISTANT PROFESSORS WITHIN 10 YEARS OF COMPLETING THEIR MD AND/OR PHD DEGREES TO SUBMIT PROPOSALS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - HARNESSING B CELL SPECIFIC CHECKPOINT MOLECULES IN LUNG CANCER - IMPACT OF SENESCENT CELLS ON LUNG TUMORIGENESIS ONE (1) RESEARCH GRANT WAS FUNDED THROUGH THE LCRF RESEARCH GRANT ON EARLY DETECTION AND PRE-NEOPLASIA IN LUNG CANCER. GIVEN THE SIGNIFICANCE AND NEED FOR EARLY DETECTION OF LUNG CANCER AND ADVANCEMENTS IN MOLECULAR SCREENING, LCRF CONTINUES TO OFFER A FUNDING MECHANISM TO SUPPORT RESEARCH PROJECTS THAT FACILITATE OR ADVANCE THE UNDERSTANDING AND CHARACTERIZATION OF PRE-NEOPLASIA OR APPROACHES FOR EARLY DETECTION OF LUNG CANCER. WORK SUPPORTED THROUGH THIS MECHANISM ADDRESSES IMPORTANT QUESTIONS IN NON-SMALL CELL AND SMALL CELL LUNG CANCER. THE PROJECTS WILL EXPLORE THE FOLLOWING: - THE SPATIAL B CELL LANDSCAPE IN LUNG SQUAMOUS PREMALIGNANT LESION THREE (3) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF-DAIICHI SANKYO-ASTRAZENECA RESEARCH GRANT ON ANTIBODY DRUG CONJUGATES, SUPPORTING RESEARCH TO STUDY HER2 DIRECTED AND TROP2 DIRECTED ADCS INCLUDING MECHANISM OF ACTION, BIOMARKERS, AND RESISTANCE MECHANISMS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - DECIPHERING THE ADC CODE: A PROTEOGENOMIC QUEST IN LUNG CANCER - PULMONARY HIGH-GRADE NEUROENDOCRINE CARCINOMAS AS INDICATIONS FOR ANTIBODY-DRUG CONJUGATES TARGETING TROP2 AND HER2 - LEVERAGING LIQUID BIOPSY TO IDENTIFY THE OPTIMAL CLINICAL NICHE FOR TROP2-TARGETING IN NSCLC IN ADDITION, THE FOUNDATION IS CURRENTLY ADMINISTRATING RESEARCH PARTNERSHIPS WITH THE LUNG CANCER MUTATION CONSORTIUM. LCRF'S PARTNERSHIP WITH THE LUNG CANCER MUTATION CONSORTIUM (LCMC) DATES BACK TO 2011 COVERING THREE CLINICAL TRIALS. THE LCMC2 CLINICAL TRIAL ENROLLED 1,000 PATIENTS VIA A NETWORK OF FOURTEEN (14) NOTABLE DOMESTIC CLINICAL RESEARCH SITES. THE CLINICAL TRIAL STUDIED THE IMPACT OF SMOKING AND TP53 MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WITH TARGETABLE MUTATIONS. THE LCMC3 CLINICAL TRIAL BEGAN IN 2017 AND HAS ENROLLED 1,000 PATIENTS VIA A NETWORK OF FIVE (5) DOMESTIC CLINICAL RESEARCH SITES. LCMC3 IS DESIGNED AS A NEOADJUVANT AND ADJUVANT TRIAL OF IMMUNE CHECKPOINT BLOCKADE FOR STAGE IB-IIIA NON-SMALL CELL LUNG CANCER. FINAL REPORTING FROM THIS CLINICAL TRIAL SHOULD BE COMPLETED IN LATE 2024. LAUNCHED IN LATE 2020, LCMC4 IS A STUDY WITH A GOAL OF ENLISTING 1,000 PATIENTS VIA A NETWORK OF 25+ DOMESTIC CLINICAL RESEARCH SITES. THE AIM OF THE CLINICAL TRIAL IS TO DETERMINE THE FEASIBILITY OF COMPREHENSIVE MOLECULAR PROFILING TO DETECT ACTIONABLE ONCOGENIC DRIVERS IN PATIENTS WITH SUSPECTED EARLY-STAGE LUNG CANCERS SCHEDULED TO UNDERGO BIOPSIES TO ESTABLISH THE DIAGNOSIS OF LUNG CANCER. SEVEN (7) GRANTS IN SUPPORT OF THE LCMC4 - LEADER NEOADJUVANT SCREENING TRIAL HAVE BEEN MADE. IN 2023, OUR RESEARCH INVESTMENT WAS FUNDED WITHOUT THE NEED FOR DEFICIT SPENDING, AND WE ARE POISED TO GROW OUR RESEARCH INVESTMENT IN THE COMING YEARS. |
| FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS: | PATIENT EDUCATION & OUTREACH: THE PATIENT EDUCATION PORTFOLIO INCLUDES PRINT AND DIGITAL EDUCATIONAL RESOURCES (PDF DOWNLOADABLE FORMAT AS WELL AS EASILY ACCESSIBLE WEBSITE CONTENT) THAT ARE PROVIDED AT NO COST. THE OVERALL GOALS OF OUR PATIENT EDUCATION MATERIALS ARE TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER, LEARN ABOUT TREATMENT OPTIONS, PARTICIPATE IN SHARED DECISION MAKING WITH THEIR CARE TEAM, MAKE DECISIONS ABOUT CLINICAL TRIALS, AND UNDERSTAND THE IMPLICATIONS OF COMPREHENSIVE BIOMARKER TESTING. PATIENTS AND CAREGIVERS NEED INFORMATION AT ALL STEPS IN THE CONTINUUM OF CARE, FROM DIAGNOSIS THROUGH TREATMENT AND BEYOND. THE LUNG CANCER RESEARCH FOUNDATION HAS A PORTFOLIO OF EDUCATIONAL RESOURCES TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER AND LEARN ABOUT THEIR TREATMENT OPTIONS. HELPING PATIENTS TO UNDERSTAND NEW TREATMENTS AND THE HOPE OFFERED BY THESE TREATMENT ADVANCES ARE KEY OBJECTIVES OF OUR EDUCATIONAL MATERIALS. WE ALSO HAVE MATERIALS DESIGNED TO EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE PROBLEM AND WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE. IN 2023, LCRF DISTRIBUTED OVER 184,000 EDUCATIONAL PIECES TO LUNG CANCER PATIENTS, CAREGIVERS, ADVOCATES AND HEALTHCARE PROFESSIONALS ACROSS THE NATION IN BOTH PRINT AND DIGITAL FORMAT. OUR WEBSITE ALSO CONTAINS LINKS TO INFORMATION AND RESOURCES, WHICH RECEIVES ON AVERAGE OF MORE THAN 200,000 PAGEVIEWS ANNUALLY. OUR CONTINUED GOAL IS TO STEADILY INCREASE OUR MATERIALS DISTRIBUTED, PARTICULARLY WITH DIGITAL DOWNLOADS AS THERE HAS BEEN A SURGE IN DEMAND FOR READILY AVAILABLE INFORMATION. THE KEY OBJECTIVES OF THE PORTFOLIO ARE TO: EMPOWER PATIENTS AND CAREGIVERS BY INCREASING THEIR KNOWLEDGE OF LUNG CANCER, BIOMARKER TESTING, CLINICAL TRIALS AND TREATMENT OPTIONS; PROVIDE AN UP-TO-DATE AND CREDIBLE SOURCE OF INFORMATION ON AVAILABLE TREATMENTS, EDUCATE PATIENTS ON WHAT TO EXPECT FROM TREATMENT AND WHAT IS CRITICAL FOR OPTIMAL OUTCOMES; PROVIDE TOOLS TO FACILITATE DISCUSSIONS BETWEEN PATIENTS AND HEALTHCARE PROVIDERS; EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE ISSUE, WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE, AND EXPLAIN THE IMPORTANCE OF EARLY DETECTION, TUMOR BIOMARKER TESTING AND CLINICAL TRIAL PARTICIPATION; SHARE PROGRESS AND IMPACT OF RESEARCH (INCLUDING THAT WHICH IS FUNDED BY LCRF), AND EXPLAIN WHY FUNDING RESEARCH IS CRUCIAL FOR THE DEVELOPMENT OF NEW TREATMENTS FOR LUNG CANCER; AND ENSURE THAT THE MATERIALS ARE CULTURALLY APPROPRIATE, AT APPROPRIATE LITERACY LEVELS, AND ACCESSIBLE THROUGH A VARIETY OF DELIVERY METHODS (ONLINE, THROUGH COMMUNITY GROUPS AND COMMUNITY HEALTHCARE PROVIDERS, PATIENT AND CAREGIVER FOCUSED EVENTS, ETC.). THE PATIENT EDUCATION MATERIALS ARE EVIDENCE-BASED AND DEVELOPED IN CONJUNCTION WITH THE EDUCATION AND ENGAGEMENT COMMITTEE, COMPOSED OF ONCOLOGISTS, RESEARCHERS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENTS/CAREGIVERS. THE PATIENT EDUCATIONAL PORTFOLIO IS ALSO CRAFTED WITH ASSISTANCE FROM THE FEEDBACK WE RECEIVE FROM OUR COMMUNITY. OUR MATERIALS ARE RATED ON AVERAGE A 4.6/5 ACCORDING TO THE FEEDBACK COLLECTED FROM INDIVIDUALS WHO DOWNLOAD OR ORDER OUR PRINT MATERIALS ON OUR WEBSITE. SAMPLE FEEDBACK INCLUDES: THANK YOU FOR PROVIDING FREE EDUCATIONAL RESOURCES. I AM A THORACIC NURSE NAVIGATOR AND PROVIDE THESE TO ALL OF MY LUNG CANCER PATIENTS. MY PATIENTS LIKE AND APPRECIATE THEM VERY MUCH. THANK YOU SO MUCH FOR PROVIDING INFORMATION TO PEOPLE TRYING TO NAVIGATE A LUNG CANCER DIAGNOSIS AND ALL THE STRESS RELATED TO THE ENTIRE PROCESS. MY MOTHER WAS RECENTLY DIAGNOSED WITH LUNG CANCER. VERY HEARTBREAKING AND A SURPRISE TO US ALL. HEARD NOTHING BUT GOOD REVIEWS ABOUT LCRF SO I LOOK FORWARD TO LEARNING ABOUT EVERYTHING AND I APPRECIATE WHAT YOU ALL DO. I LOVE THE UPDATED LIVING WITH LUNG CANCER BOOKLET. I READ IT FROM COVER TO COVER AND FEEL THAT IT WAS VERY NICELY DONE. IT IS DEFINITELY VERY COMPREHENSIVE IN THAT IT INCLUDES COPING WITH DIAGNOSIS/TREATMENT, INFORMATION ABOUT OUR NEWER TARGETED AND IMMUNOTHERAPIES, AND TREATMENT SIDE-EFFECT MANAGEMENT. GOOD JOB ON YOUR END! LUNG CANCER SUPPORT LINE: OUR LUNG CANCER SUPPORT LINE IS A TOLL-FREE NUMBER (844)-835-4325, AND IS AVAILABLE TO ANYONE AFFECTED BY LUNG CANCER, PRIMARILY LUNG CANCER PATIENTS AND CAREGIVERS. THE SUPPORT LINE OPERATES MONDAY-FRIDAY 9AM-5PM ET AND IS EQUIPPED WITH EXTENSIVE AND UP-TO-DATE RESOURCE GUIDES FOR COMMON NEEDS AND SERVICES FOR LUNG CANCER PATIENTS SUCH AS FINANCIAL ASSISTANCE, TRANSPORTATION OR LODGING TO/FROM MEDICAL APPOINTMENTS, SUPPORT GROUPS, AND MUCH MORE. LUNG CANCER PATIENTS AND THEIR CAREGIVERS MAY CALL OR EMAIL THE PROGRAM AS OFTEN AS THEY WISH, AND THE SERVICE IS OFFERED FREE OF CHARGE. THE LUNG CANCER SUPPORT LINE HELPS FILL AN UNMET NEED BY PROVIDING PERSONALIZED, ONE-ON-ONE SUPPORT TO CALLERS WHO ARE FACING THE CHALLENGES OF LUNG CANCER. IN 2023, WE HAD OVER 1,000 INQUIRIES COME IN THROUGH THE SUPPORT LINE. OVER HALF OF CALLERS ARE NEWLY DIAGNOSED PATIENTS OR CAREGIVERS OF THOSE WHO ARE RECENTLY DIAGNOSED, PROVING THAT THE SUPPORT LINE PROVIDES A TIMELY SERVICE FOR THOSE SEEKING SUPPORT. MANY SUPPORT LINE INQUIRIES ALSO COME IN FROM HEALTHCARE INSTITUTIONS OR COMMUNITY-BASED INSTITUTIONS LOOKING FOR RESOURCES FOR THEIR PATIENTS. OUR CONTINUED GOAL FOR THE SUPPORT LINE IS TO STRENGTHEN OUR COMMUNICATION WITH THOSE WHO ARE NEWLY DIAGNOSED AND ENGAGED IN OUR EDUCATIONAL PROGRAMS. WE ALSO HOPE TO INCREASE OUR SUPPORT LINE REACH BY 10% OVER THE NEXT YEAR VIA TARGETED OUTREACH AND PROMOTION OF OUR SERVICES. THROUGH THE SUPPORT LINE, WE: PROVIDE A QUALITY SERVICE TO PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, BY OFFERING SUPPORT IN THEIR AREA OF NEED DURING ONE-ON-ONE INTERACTIONS; EMPOWER PATIENTS AND CAREGIVERS THROUGH CONNECTIONS TO RESOURCES (EDUCATION, ASSISTANCE, AND SUPPORT); ENHANCE PATIENTS AND CAREGIVERS' UNDERSTANDING OF LUNG CANCER; INCREASE NUMBER OF SUPPORT INQUIRIES AND TOTAL NUMBER OF INTERACTIONS BETWEEN LCRF SUPPORT SERVICES STAFF AND PERSON SEEKING SUPPORT; AND INCREASE SUPPORT TO UNDERSERVED POPULATIONS BY DEVELOPING RELEVANT RESOURCE GUIDES THAT ADDRESS THE NEEDS OF SPECIFIC UNDERSERVED POPULATIONS (I.E.: PEOPLE OF COLOR, UNINSURED, LGBTQ+, NON-ENGLISH SPEAKING, CAREGIVERS, YOUNG ADULTS). PATIENT EDUCATION PROGRAMMING (VIRTUAL AND IN-PERSON): BARRIERS TO ACCESSING UP-TO-DATE, EXPERT INFORMATION ON LUNG CANCER RESEARCH ADVANCEMENTS AND TREATMENTS ARE EVIDENT BASED ON STIGMA SURROUNDING LUNG CANCER. OUR PATIENT EDUCATION PROGRAMMING AIMS TO INCREASE THE ACCESSIBILITY OF DISEASE AWARENESS AND INFORMATION TO THE LUNG CANCER COMMUNITY BY CREATING EVENTS WHERE LUNG CANCER RESEARCHERS, CLINICIANS, AND OTHER EXPERTS DISCUSS SCIENTIFIC ADVANCEMENT, IMPORTANT UPDATES IN TREATMENTS, AS WELL AS INFORMATION FOR IMPROVING QUALITY OF LIFE WHILE RECEIVING TREATMENT. LCRF ALSO AIMS TO HOST TOPICS THAT WOULD SPECIFICALLY HELP SUPPORT UNDERSERVED POPULATIONS, SUCH AS PEOPLE OF COLOR, THOSE IN LOW SOCIOECONOMIC GROUPS, RURAL DEMOGRAPHICS, AND SPANISH-SPEAKING POPULATIONS, ALL OF WHICH EXPERIENCE A RANGE OF HEALTH DISPARITIES. ATTENDEES, BOTH VIRTUAL AND IN-PERSON, HAVE THE OPPORTUNITY TO LEARN ABOUT LUNG CANCER, TREATMENT OPTIONS AND ADVANCES IN RESEARCH, CLINICAL TRIALS AND AVAILABLE RESOURCES. THEY CAN POSE QUESTIONS TO LUNG CANCER EXPERTS, SHARE THEIR OWN PERSONAL EXPERIENCE, AND ENGAGE WITH THEIR PEERS, FORGING CONNECTIONS AND SUPPORT. THIS PROGRAM ALLOWS PATIENTS AND THEIR FAMILIES TO BECOME MORE INFORMED ABOUT LUNG CANCER AND THEIR OPTIONS FOR NAVIGATING LIFE WITH THEIR DISEASE. THE LEARNING OBJECTIVES OF OUR EDUCATIONAL PROGRAMS ARE: 1. PROVIDE UP-TO-DATE EDUCATION AND INFORMATION ABOUT LUNG CANCER DIAGNOSIS AND TREATMENT, SO OUR AUDIENCE HAS A RELIABLE SOURCE TO TURN TO FOR ACCURATE AND TIMELY INFORMATION; 2. INFORM ABOUT NEW ADVANCEMENTS IN THE FIELD OF LUNG CANCER RESEARCH AND THE TREATMENT LANDSCAPE; 3. PROVIDE OPPORTUNITY FOR DIALOGUE AND A SENSE OF CONNECTION AND COMMUNITY; 4. HIGHLIGHT RESEARCH ADVANCEMENTS, NEWLY DISCOVERED TREATMENT OPTIONS, BEST PRACTICES AND STANDARDS OF CARE FOR PATIENTS UNDERGOING TREATMENT, AND PSYCHOSOCIAL SUPPORT FOR PATIENTS AND THEIR CAREGIVERS; 5. ENSURE AWARENESS OF AND ACCESS TO IMPORTANT LUNG CANCER RESOURCES AND PROGRAMS OFFERED THROUGH LCRF AND ITS PARTNERS. SINCE ITS INCEPTION IN MARCH 2020, WE'VE HAD OVER 7,500 REGISTRANTS FOR OUR #TOGETHERSEPARATELY VIRTUAL EVENTS WITH AN AVERAGE ATTENDANCE RECORD OF OVER 100 INDIVIDUALS PER WEBINAR. MOST OF THE ATTENDEES IN THIS SERIES ARE LUNG CANCER PATIENTS, SURVIVORS, ADVOCATES, CAREGIVERS, AND COMMUNITY PROVIDERS. OUR GOAL IS TO CONTINUE THE SERIES, WHILE FOCUSING ON THE BIGGEST AREAS OF UNMET NEEDS IN THE LUNG CANCER COMMUNITY. ADDITIONALLY, SINCE 2022, WE'VE REINTRODUCED OUR IN-PERSON PROGRAMMING WITH THE LAUNCH OF OUR LCRF TOGETHER IN-PERSO |
| FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS, CONTINUED: | ADDITIONALLY, SINCE 2022, WE'VE REINTRODUCED OUR IN-PERSON PROGRAMMING WITH THE LAUNCH OF OUR LCRF TOGETHER IN-PERSON EDUCATIONAL PROGRAM SERIES. WE HOSTED OUR FIRST LCRF TOGETHER PROGRAM IN CHICAGO, ILLINOIS ON JUNE 28, 2022. THIS EVENT HAD OVER 50 PEOPLE IN ATTENDANCE, INCLUDING PATIENTS AND CAREGIVERS, THOSE WHO HAVE LOST A LOVED ONE, AS WELL AS HEALTHCARE PROFESSIONALS AND INDUSTRY SPONSORS. |
| FORM 990, PART VI, SECTION A, LINE 2 | MARY ANN TIGHE AND AARON M. TIGHE - FAMILY RELATIONSHIP MARY ANN TIGHE AND RAYMOND E. CHALME - BUSINESS RELATIONSHIP |
| FORM 990, PART VI, SECTION B, LINE 11B | A DRAFT OF THE RETURN IS REVIEWED FIRST BY THE EXECUTIVE COMMITTEE AND THEN BY THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE BOARD REVIEWS THE CONFLICT OF INTEREST POLICY ANNUALLY, AND ASKS ALL BOARD MEMBERS AND EMPLOYEES TO DISCLOSE ANY CONFLICTS OR POTENTIAL CONFLICTS. IN ADDITION, ALL CONTRACTS ARE REVIEWED FOR KNOWN OR POTENTIAL CONFLICTS BY THE EXECUTIVE DIRECTOR, SR. DIRECTOR FINANCE & ADMINISTRATION AND THE EXECUTIVE COMMITTEE ON AN ON-GOING BASIS. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE EXECUTIVE COMMITTEE OF THE BOARD LOOKS AT COMPENSATION SURVEYS AND ALSO COMPARES SALARIES IN SIMILAR ORGANIZATIONS TO DETERMINE THE REASONABLENESS OF SALARIES FOR KEY EMPLOYEES. THE EXECUTIVE COMMITTEE ALSO CONSIDERS OTHER PERFORMANCE-BASED CRITERIA WHICH INCLUDES A WRITTEN PERFORMANCE APPRAISAL OF THE EXECUTIVE DIRECTOR. |
| FORM 990, PART VI, SECTION C, LINE 19 | FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. ALL OTHER DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON RECEIPT OF A WRITTEN REQUEST. |
| FORM 990, PART XI, LINE 9: | RETURNED GRANT FUNDS 87,950. |
| Software ID: | |
| Software Version: |